TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20371785
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy for 12 months (group 2, n = 181)
Study: 20371785
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy for 6 months (group 1)
Study: 20371785
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy for 12 months (group 2)
Study: 17325227
Drug: Fosmidomycin‐clindamycin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin‐clindamycin therapy given every 12 h for 3 days
Study: 17325227
Drug: Sulfadoxine‐pyrimethamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (single oral dose)
Study: 9539595
Drug: Selective group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective group (R and MC nerves blocked with 10 mL of 2% lidocaine each; M and U nerves blocked with 10 mL of 0.5% bupivacaine each)
Study: 9539595
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (each of the four nerves infiltrated with 10 mL of a mixture of 2% lidocaine and 0.5% bupivacaine)
Study: 8091142
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg bid
Study: 20510987
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy only (Control)
Study: 30945504
Drug: Internal heat-type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal heat-type acupuncture needle therapy (IHTAN), 42 ℃, 20 min, once a week for 4 weeks
Study: 30945504
Drug: Warm needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needle moxibustion therapy, once every other day for 4 weeks
Study: 28917230
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg green coffee bean extract for 8 weeks
Study: 1673495
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 (40 mg by mouth)
Study: 7047329
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intrathecal immunoglobulin (Ig) therapy: 10 g Ig as a short infusion on two consecutive days, plus 500 mg by intrathecal injection every second day for bacterial infections and every fifth day for viral infections.
Study: 7047329
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received usual therapy only, principally antibiotics for purulent meningitis.
Study: 24622414
Drug: Alefacept (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (15 mg intramuscularly per week for two 12-week courses, separated by a 12-week pause)
Study: 18813407
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/kg (group K)
Study: 18813407
Drug: Pethidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.5 mg/kg (group P)
Study: 12781852
Drug: 400 microg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg/d folic acid supplement
Study: 10692621
Drug: Systemic lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic lidocaine (2 mg/kg bolus followed by 2 mg kg(‐1)h(‐1) infusion)
Study: 10692621
Drug: Regional lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional lidocaine (40 ml lidocaine, 0.05%)
Study: 10692621
Drug: Control (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (40 ml NaCl, 0.9%)
Study: 9459116
Drug: Intravenous polyvalent
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polyvalent immunoglobulins (IVIG) at a dose of 1 g/kg for 3 days
Study: 1585493
Drug: Both EC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both EC and UW solutions
Study: 26509765
Drug: i‐gel (laryngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: i‐gel (laryngeal mask)
Study: 24622832
Drug: Tryptophan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (2 x 500 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Study: 24622832
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 x 5 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Study: 20435245
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of tramadol 100 mg
Study: 20435245
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of tramadol 100 mg
Study: 19014839
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of lamotrigine (100 mg)
Study: 19014839
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of lamotrigine (100 mg)
Study: 14675880
Drug: Bisoprolol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 1.25 mg (increased to a maximum dose of 5 mg per day)
Study: 14675880
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy with diuretic and ACE inhibitor)
Study: 12434619
Drug: 15% in-office
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% in-office hydrogen peroxide tooth-whitening touch-up agent
Study: 1828225
Drug: Monophasic combined
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combined oral contraceptive (130 micrograms ethinylestradiol + 150 micrograms desorgestrel)
Study: 1828225
Drug: Triphasic combined
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic combined oral contraceptive (30 micrograms ethinylestradiol + 50 micrograms levonorgestrel for 6 days, followed by 40 micrograms ethinylestradiol + 75 micrograms levonorgestrel for 5 days and 30 micrograms ethinylestradiol + 125 micrograms levonorgestrel for 10 days)
Study: 6123122
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg mepindolol
Study: 6123122
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mepindolol
Study: 31292969
Drug: High-dose tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tablets (LF 60 mg/d, LPO 7.8 mg/d)
Study: 31292969
Drug: Low-dose tablets
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tablets (LF 20 mg/d, LPO 2.6 mg/d)
Study: 19150955
Drug: First-line combination
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line combination therapy with capecitabine and irinotecan (specific dosage and duration not mentioned)
Study: 15076791
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg.wk(‐1), intramuscularly)
Study: 9847429
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray, 256 microgram
Study: 9847429
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous suspension, 200 microgram
Study: 8021907
Drug: Propranolol (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-120 mg)
Study: 8021907
Drug: Verapamil (80-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80-200 mg)
Study: 2640054
Drug: FDP 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDP 20 g
Study: 811471
Drug: 30 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mug TRH (single injection)
Study: 811471
Drug: 30 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mug TRH (six injections with 30 minutes interval)
Study: 29665158
Drug: Gastrointestinal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal delivery oral immunotherapy (GIDOIT) with peanut capsules, 2 to 400 mg of peanut protein daily for 24 weeks
Study: 24445356
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 injection in the Spleen‐6 (SP‐6) acupuncture point
Study: 24445356
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection in a nonacupuncture point
Study: 24445356
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 injection
Study: 8367870
Drug: Combined perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined perioperative infusion of nifedipine (10 micrograms/kg/h) and metoprolol (12 micrograms/kg/h)
Study: 2558882
Drug: Meals with
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals with added table salt (4.25 g)
Study: 27467589
Drug: Valencia model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valencia model of waking hypnosis plus cognitive‐behavioral therapy (VMWH‐CBT)
Study: 16915107
Drug: Albumin administration
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin administration (300 mL of 20% albumin solution on the first day, then 200 mL/day if serum albumin <31 g/dL)
Study: 12419083
Drug: Intranasal estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal estradiol 150 microg/day
Study: 12419083
Drug: Intranasal estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal estradiol 300 microg/day
Study: 10599387
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream 0.1% applied every evening and hydroquinone lotion 3% applied every morning
Study: 1777832
Drug: Budesonide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 200 micrograms once daily in each nostril
Study: 31240995
Drug: BUD/FORM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FORM plus I+T (160/4.5 µg; two inhalations twice daily via Turbuhaler®) + I (20 µg per inhalation, two inhalations four times daily) + T (100 mg bid)
Study: 26281342
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 4 mg of lornoxicam
Study: 22032053
Drug: Early atropine-dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early atropine-dobutamine stress echocardiography (EA-DSE); atropine started at dobutamine infusion rate of 20 microg/kg/min, max dose 2.0 mg.
Study: 18765698
Drug: Episodic antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Episodic antiretroviral therapy
Study: 17971716
Drug: Continuous antiretroviral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antiretroviral therapy
Study: 18617640
Drug: Current smokers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current smokers on continuous HIV treatment
Study: 26987315
Drug: Unified protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified protocol combined with treatment-as-usual
Study: 26987315
Drug: Waiting-list with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list with treatment-as-usual
Study: 25609654
Drug: Probiotics (10^9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (10^9 cfu Bifobacterium bifidum A218, 10^9 cfu Bifobacterium catenulatum A302, 10^9 cfu Bifobacterium longum A101, 10^9 cfu Lactobacillus plantarum A87 daily for six months)
Study: 25609654
Drug: Placebo (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin capsules for six months)
Study: 23532298
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (HbA1c-based treatment, n = 65)
Study: 18991077
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral micronized estradiol therapy
Study: 18991077
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral micronized estradiol therapy
Study: 16842669
Drug: IL‐6/‐572C/G genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐6/‐572C/G genotype
Study: 16842669
Drug: IL‐6/‐572 C/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐6/‐572 C/G polymorphism
Study: 9089901
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (5.2 g of concentrated fish oil triglyceride, 1.60 g/day EPA and 1.04 g/day DHA)
Study: 9089901
Drug: Placebo (5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5.2 g corn oil)
Study: 26489511
Drug: Danhong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong injection
Study: 31160171
Drug: Ribociclib 600
Normalized name: letrozole 2.5 MG / ribociclib 600 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 600 mg/d (3 weeks on/1 week off) with letrozole 2.5 mg/d (continuous)
Study: 26632082
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of guaifenesin (age‐based doses of 100‐400 mg)
Study: 20013603
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (group G, N = 193)
Study: 18667293
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy for 12 weeks
Study: 16248238
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Droplet‐pill (DS) combined with trimetazidine (TMZ)
Study: 8277091
Drug: Sulodexide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (600 LRU intramuscular injection for 1 month, followed by 500 LRU oral capsules twice daily)
Study: 1187285
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg oral dose of a new xanthone drug
Study: 16613260
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus Sanpu Xinnao Xin granule (Group B)
Study: 16613260
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus Xiaoyao pill (Group C)
Study: 10655394
Drug: FluMist vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluMist vaccine (cold-adapted H1N1, H3N2, and B influenza viruses)
Study: 1564689
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rinsing with 0.2 percent neutral NaF solution and chewing 2.2 mg NaF tablet
Study: 1564689
Drug: Fluoride tablets
Normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride tablets (2.2 mg NaF tablet)
Study: 1564689
Drug: Fluoride rinse
Normalized name: ACT Fluoride Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride rinse (0.2 percent neutral NaF solution)
Study: 4076202
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nicardipine + Metoprolol)
Study: 4076202
Drug: Nicardipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (10 mg) during dynamic exercise
Study: 4076202
Drug: Metoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10 mg) during dynamic exercise
Study: 4076202
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nicardipine + Metoprolol) during dynamic exercise
Study: 26683007
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of HA/Col
Study: 25060156
Drug: Capsaicin and
Normalized name: Capsaicin and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin and dihydrocapsaicin combination in 30c potency
Study: 22564839
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ofloxacin daily
Study: 22564839
Drug: 1,600 mg
Normalized name: omega-3/dha/epa/fish oil 1,600 mg-500 mg-800 mg/5 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,600 mg ofloxacin daily
Study: 20575288
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with acupoint-injection of botulinum toxin A (Group A)
Study: 20575288
Drug: Acupoint-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-injection of botulinum toxin A (Group B)
Study: 10502572
Drug: Suction applied
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suction applied under ophthalmic drapes
Study: 10502572
Drug: No suction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No suction used under ophthalmic drapes
Study: 24992553
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg daily
Study: 27240198
Drug: Iodine group
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine group (30 patients); aqueous iodine solution applied intrapleurally.
Study: 27240198
Drug: Doxycycline group
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline group (34 patients); 200 mg of Doxycycline given.
Study: 27240198
Drug: Drainage group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drainage group (35 patients); Lidocaine solution only applied.
Study: 8831399
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day vesnarinone
Study: 8831399
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day vesnarinone
Study: 25579777
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide pneumococcal vaccine (PPV23)
Study: 20117269
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7)
Study: 15578203
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg kg(‐1) body mass)
Study: 12168365
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (without hypothermia)
Study: 10534584
Drug: Maprotiline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (up to 150 mg daily)
Study: 10534584
Drug: Paroxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (up to 30 mg daily)
Study: 10534584
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (diphenhydramine hydrochloride up to 37.5 mg daily)
Study: 30737046
Drug: Long-term weekly
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term weekly iron supplementation
Study: 25549765
Drug: LPS (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (0.3 ng/kg body weight) injection in trained (T) group
Study: 25549765
Drug: LPS (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (0.3 ng/kg body weight) injection in untrained (UT) group
Study: 15377055
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements and psychological therapy
Study: 9553912
Drug: Dithranol ointment
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol ointment treatment
Study: 3323113
Drug: iohexol 350
Normalized name: iohexol 350 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 350 mg I/mL
Study: 3323113
Drug: ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate 320 mg I/mL
Study: 28872898
Drug: Coping Skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping Skills Training (CST) program - six weekly telephone sessions plus access to a study website
Study: 22420841
Drug: Azithromycin (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (one drop twice daily for 3 days)
Study: 22420841
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 drop 4 times daily until complete re-epithelialization)
Study: 23994420
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg/day
Study: 18681754
Drug: Dipyridamole 200
Normalized name: dipyridamole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 200 mg/day
Study: 6813481
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) 3 mg bid
Study: 26584195
Drug: Anakinra (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (recombinant interleukin‐1 receptor antagonist)
Study: 15195012
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s
Study: 15195012
Drug: 140 ml
Normalized name: syringe, disposable, 140 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 ml of contrast material at 4 ml/s
Study: 11402632
Drug: tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine 2 mg bid (total 4 mg/d)
Study: 11402632
Drug: trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trospium chloride 15 mg tid (total 45 mg/d)
Study: 11402632
Drug: oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxybutynin 5 mg tid (total 15 mg/d)